Carlsmed Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	56.44	50.51	27.17	13.78
Revenue Growth (YoY)	74.90%	85.94%	97.16%	-
Cost of Revenue	13.61	12.47	7.12	3.88
Gross Profit	42.83	38.04	20.05	9.9
Selling, General & Admin	57.91	51.6	29.87	21.1
Research & Development	19.05	17.02	14.3	7.4
Total Operating Expenses	76.96	68.61	44.17	28.49
Operating Income	-34.13	-30.57	-24.12	-18.59
Interest Income	3.21	2.7	1.33	0.33
Interest Expense	-1.38	-1.43	-1.32	-0.64
Other Non-Operating Income (Expense)	-0.3	-0.33	-0.14	-
Total Non-Operating Income (Expense)	1.53	0.94	-0.14	-0.31
Pretax Income	-32.6	-29.63	-24.26	-18.9
Net Income	-32.6	-29.63	-24.26	-18.9
Net Income Attributable to Preferred Dividends	-	0.58	0.59	-
Net Income to Common	-32.6	-30.22	-24.85	-18.9
Shares Outstanding (Basic)	20	14	4	4
Shares Outstanding (Diluted)	20	14	4	4
Shares Change (YoY)	377.46%	249.74%	4.62%	-
EPS (Basic)	-2.51	-2.12	-6.11	-4.86
EPS (Diluted)	-2.51	-2.12	-6.11	-4.86
Free Cash Flow	-34.47	-29.62	-25.65	-17.62
Free Cash Flow Per Share	-1.74	-2.08	-6.31	-4.53
Gross Margin	75.89%	75.31%	73.80%	71.88%
Operating Margin	-60.48%	-60.53%	-88.80%	-134.93%
Profit Margin	-57.76%	-58.67%	-89.30%	-137.16%
FCF Margin	-61.07%	-58.64%	-94.41%	-127.85%
EBITDA	-33.79	-30.29	-23.98	-18.46
EBITDA Margin	-59.87%	-59.97%	-88.26%	-133.94%
EBIT	-34.13	-30.57	-24.12	-18.59
EBIT Margin	-60.48%	-60.53%	-88.80%	-134.93%

SEC Filings: 10-K · 10-Q